151 related articles for article (PubMed ID: 14666734)
1. Combined immunotherapy with intracavital injection of activated lymphocytes, monocyte-derived dendritic cells and low-dose OK-432 in patients with malignant effusion.
Morisaki T; Matsumoto K; Kuroki H; Kubo M; Baba E; Onishi H; Tasaki A; Nakamura M; Inaba S; Katano M
Anticancer Res; 2003; 23(6a):4459-65. PubMed ID: 14666734
[TBL] [Abstract][Full Text] [Related]
2. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of 5-year survival among breast cancer patients with malignant pleural effusion receiving intrapleural OK-432 followed by adoptive transfer with cultured effusion lymphocytes].
Kan N
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1559-61. PubMed ID: 14619463
[TBL] [Abstract][Full Text] [Related]
4. [Intrapleural administration with OK-432 and cultured autologous pleural effusion lymphocytes for breast cancer patients with malignant pleural effusions: analysis of 84 patients over a 14-year period].
Kan N
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1796-800. PubMed ID: 10560397
[TBL] [Abstract][Full Text] [Related]
5. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
6. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment.
Yamaguchi Y; Ohshita A; Kawabuchi Y; Hihara J; Miyahara E; Noma K; Toge T
Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836
[TBL] [Abstract][Full Text] [Related]
7. [T cell receptor V beta repertoire of locoregional lymphocytes in malignant effusions].
Miyahara E; Yamaguchi Y; Hihara J; Noma K; Funakoshi M; Takashima I; Sawamura A; Toge T
Gan To Kagaku Ryoho; 1995 Sep; 22(11):1622-5. PubMed ID: 7574776
[TBL] [Abstract][Full Text] [Related]
8. A new approach to the treatment of malignant effusion.
Li DJ; Wang YR; Tan XY; Wang HZ; Yao XD; Ba DN
Chin Med J (Engl); 1990 Dec; 103(12):998-1002. PubMed ID: 2127253
[TBL] [Abstract][Full Text] [Related]
9. Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion.
Nio Y; Nagami H; Tamura K; Tsubono M; Nio M; Sato M; Kawabata K; Hayashi H; Shiraishi T; Imai S; Tsuchitani T; Mizuta J; Nakagawa M; Fukumoto M
Br J Cancer; 1999 May; 80(5-6):775-85. PubMed ID: 10360655
[TBL] [Abstract][Full Text] [Related]
10. [Clinical evaluation of intrapleural or peritoneal administration of lentinan and OK-432 for malignant effusion].
Kawaoka T; Yoshino S; Hazama S; Tangoku A; Oka M
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1562-5. PubMed ID: 14619464
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
[TBL] [Abstract][Full Text] [Related]
12. [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect].
Kan N; Okino T; Nakanishi M; Sato K; Mise K; Teramura Y; Yamasaki S; Hori T; Ohgaki K; Tobe T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1455-61. PubMed ID: 2786379
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of OK-432 in patients with malignant pleural effusion due to non-small cell lung cancer.
Kasahara K; Shibata K; Shintani H; Iwasa K; Sone T; Kimura H; Nobata K; Hirose T; Yoshimi Y; Katayama N; Ishiura Y; Kita T; Nishi K; Nakatsumi Y; Ryoma Y; Fujimura M; Nakao S
Anticancer Res; 2006; 26(2B):1495-9. PubMed ID: 16619563
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
Katano M; Morisaki T; Koga K; Nakamura M; Onishi H; Matsumoto K; Tasaki A; Nakashima H; Akiyoshi T; Nakamura M
Anticancer Res; 2005; 25(6A):3771-6. PubMed ID: 16302738
[TBL] [Abstract][Full Text] [Related]
15. Profile of T-cell receptor V beta gene usage of cytotoxic T cells induced by intrapleural administration of a streptococcal preparation, OK432, in malignant effusions.
Miyahara E; Yamaguchi Y; Hihara J; Noma K; Toge T
J Exp Ther Oncol; 1996 Jul; 1(4):242-50. PubMed ID: 9414411
[TBL] [Abstract][Full Text] [Related]
16. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
[TBL] [Abstract][Full Text] [Related]
17. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study.
Stemmler HJ; Salat C; Lindhofer H; Menzel H; Untch M; Kahlert S; Konecny G; Sauer H; Ledderose G; Heinemann V; Kolb HJ
Anticancer Res; 2005; 25(4):3047-54. PubMed ID: 16080564
[TBL] [Abstract][Full Text] [Related]
19. [Clinical effects and immunological analysis of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion of gastric carcinoma].
Hazama S; Oka M; Yoshino S; Iizuka N; Wadamori K; Yamamoto K; Hirazawa K; Wang F; Ogura Y; Masaki Y
Gan To Kagaku Ryoho; 1995 Sep; 22(11):1595-7. PubMed ID: 7574768
[TBL] [Abstract][Full Text] [Related]
20. Induction of inflammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion: role of interferon-gamma in enhancement of surface expression of ICAM-1 on tumor cells in vivo.
Kitsuki H; Katano M; Ikubo A; Morisaki T; Anann K; Tanaka M; Torisu M
Clin Immunol Immunopathol; 1996 Mar; 78(3):283-90. PubMed ID: 8605704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
